SCHERING's IMDUR HAD 26% OF GROWING ISOSORBIDE MONONITRATE MARKET
Executive Summary
SCHERING's IMDUR HAD 26% OF GROWING ISOSORBIDE MONONITRATE MARKET in the six months ended Sept. 30, according to data from IMS America's NPA Plus data service. On a more than four-fold jump in scripts in its second six-month period on the U.S. market, Imdur generated 316,000 scripts between April and September of this year. In its first six-month period on the market, the product generated 73,000 scripts. In retail dollars, Imdur generated over $8 mil. in sales in the March-September period.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: